<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445885</url>
  </required_header>
  <id_info>
    <org_study_id>LATE-MI</org_study_id>
    <nct_id>NCT02445885</nct_id>
  </id_info>
  <brief_title>Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction</brief_title>
  <acronym>LATE-MI</acronym>
  <official_title>Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Engstrom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although recommended therapy for patients with ST-segment elevation myocardial infarction is&#xD;
      primary PCI, it remains unestablished whether patients with a symptom duration of more 12&#xD;
      hours benefit from acute revascularisation.&#xD;
&#xD;
      This study aims to investigate whether acute intervention is superior to subacute&#xD;
      intervention in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recommended therapy for patients with ST-segment elevation myocardial infarction (STEMI)&#xD;
      is to restore normal coronary blood flow with timely reperfusion by percutaneous coronary&#xD;
      intervention (PCI), and thereby minimize the extent of cell death and preserving cardiac&#xD;
      function. The duration of ischemia and timely PCI are major determinants for the size of the&#xD;
      myocardial infarction and prognosis. Thus, acute PCI should be performed within 12 hours&#xD;
      after symptom onset. The effect of PCI and timing of PCI are, however, much more uncertain&#xD;
      for late presenters who contact the health service &gt; 12 hours from symptom. Thus, it is still&#xD;
      unknown whether late presenters should be treated with acute PCI or medical treatment with&#xD;
      delayed PCI (24-72 h after first medical contact).&#xD;
&#xD;
      The study investigates the effect on final salvage index evaluated by magnetic resonance&#xD;
      imaging of acute PCI of late presenters.&#xD;
&#xD;
      The overall objective of the study is to investigate whether late presenters may benefit from&#xD;
      acute PCI, and thus whether to extend the currently recommended time limit of 12 hours for&#xD;
      acute PCI in patients with STEMI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final salvage index evaluated by MRI</measure>
    <time_frame>3 months</time_frame>
    <description>MRI within 48 timer after index admission will be used to measure are at risk (AAR, T2-weighted) whereas final infarct size (IZ) will be measured be means of gadolinium after 3 months. Final salvage index is (AAR-IZ)/AAR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final infarct size</measure>
    <time_frame>3 months</time_frame>
    <description>Please see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial salvage index</measure>
    <time_frame>&lt;48 hours</time_frame>
    <description>As for primary endpoint but IZ is measured within the index admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute infarct size</measure>
    <time_frame>&lt;48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction (MVO)</measure>
    <time_frame>Within index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Index admission and 3 months</time_frame>
    <description>Measured by MRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Left Ventricular (LV) volumes</measure>
    <time_frame>Index admission and 3 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>ST-segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Acute PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute re-opening of the occluded coronary artery including premedication as for primary PCI within 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subacute PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard subacute re-opening of the occluded coronary artery including premedication as for subacute PCI within 72 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>Guideline directed Percutaneous Coronary Intervention</description>
    <arm_group_label>Acute PCI</arm_group_label>
    <arm_group_label>Subacute PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria:&#xD;
&#xD;
          -  Patients more than 18 years of age.&#xD;
&#xD;
          -  STEMI &gt; 12 hours and &lt; 36 hours.&#xD;
&#xD;
          -  Clinical stable, i.e. no on going angina, hemodynamically stable (systolic BP &gt; 90)&#xD;
             and Killip class &lt; 3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical instability which requires an acute invasive strategy.&#xD;
&#xD;
          -  Left main occlusion or multivessel disease which requires CABG.&#xD;
&#xD;
          -  Previous Q-wave infarction in the current infarct related artery.&#xD;
&#xD;
          -  Left Bundle Branch Block (LBBB).&#xD;
&#xD;
          -  Severe renal insufficiency.&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Chronic atrial fibrillation.&#xD;
&#xD;
          -  Previous Coronary Artery Bypass Surgery (CABG).&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Other severe illness with life expectancy less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Nepper-Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Nepper-Christensen, MD</last_name>
    <phone>+4535457586</phone>
    <email>lars.nepper@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Engstrøm, MDSci, PhD</last_name>
    <phone>+4535452017</phone>
    <email>thomas.engstroem@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Nepper-Christensen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas Engstrøm, DSci, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Terkelsen CJ, Sørensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, Vach W, Johnsen SP, Thuesen L, Lassen JF. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010 Aug 18;304(7):763-71. doi: 10.1001/jama.2010.1139.</citation>
    <PMID>20716739</PMID>
  </reference>
  <reference>
    <citation>Carlsson M, Ubachs JF, Hedström E, Heiberg E, Jovinge S, Arheden H. Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging. 2009 May;2(5):569-76. doi: 10.1016/j.jcmg.2008.11.018.</citation>
    <PMID>19442942</PMID>
  </reference>
  <results_reference>
    <citation>Busk M, Kaltoft A, Nielsen SS, Bøttcher M, Rehling M, Thuesen L, Bøtker HE, Lassen JF, Christiansen EH, Krusell LR, Andersen HR, Nielsen TT, Kristensen SD. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for &lt;12 h vs. 12-72 h. Eur Heart J. 2009 Jun;30(11):1322-30. doi: 10.1093/eurheartj/ehp113. Epub 2009 Apr 8.</citation>
    <PMID>19357105</PMID>
  </results_reference>
  <results_reference>
    <citation>Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, Nekolla SG, Schlotterbeck K, Schühlen H, Pache J, Seyfarth M, Martinoff S, Benzer W, Schmitt C, Dirschinger J, Schwaiger M, Kastrati A; Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005 Jun 15;293(23):2865-72.</citation>
    <PMID>15956631</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Thomas Engstrom</investigator_full_name>
    <investigator_title>Chief Consultant</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Late presenters</keyword>
  <keyword>Primary percutaneous coronary intervention</keyword>
  <keyword>Reperfusion</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Duration of ischemia</keyword>
  <keyword>Cardiovascular magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

